閾剁墝浼氬憳绗?span style="font-size:1.5em;color:#f21">2骞滁/div> 璁块棶閲廁 3480510 缃戝潃:antibody.cnreagent.com 鍦ㄧ嚎鐣欒█
浜у搧鎼滅储
鎶椾綋 >> 鍏朵粬鎶椾綋
12鍙锋煋鑹蹭綋寮€鏀鹃槄璇绘29鎶椾綋
12鍙锋煋鑹蹭綋寮€鏀鹃槄璇绘29鎶椾綋鍥剧墖
浜よ揣鏈烔 1鍛?/span>
绱㈠彇璧勬枡鍙婃姤浠饵/span>
浜よ揣鏈烔 1鍛?/td>
浜у搧鍒悕: Anti-C12orf29
Anti-chromosome 12 open reading frame 29 Antibody
浜у搧浠嬬粛
闈舵爣锛欬p style="text-indent: 2em;">C12orf29


浜у搧鍒悕锛欬p style="text-indent: 2em;">C12orf29锛 chromosome 12 open reading frame 29锛 chromosome 12 open reading frame 29锛 uncharacterized protein C12orf29锛 12鍙锋煋鑹蹭綋寮€鏀鹃槄璇绘29锛


鑳屾櫙淇℃伅锛欬div style="text-indent: 2em;">Encoding over 1,100 genes within 132 million bases, chromosome 12 makes up about 4.5% of the human genome. A number of skeletal deformities are linked to chromosome 12 including hypochondrogenesis, achondrogenesis and Kniest dysplasia. Noonan syndrome, which includes heart and facial developmental defects among the primary symptoms, is caused by a mutant form of PTPN11 gene product, SH-PTP2. Chromosome 12 is also home to a homeobox gene cluster which encodes crucial transcription factors for morphogenesis, and the natural killer complex gene cluster encoding C-type lectin proteins which mediate the NK cell response to MHC I interaction. Trisomy 12p leads to facial development defects, seizure disorders and a host of other symptoms varying in severity depending on the extent of mosaicism and is most severe in cases of complete trisomy. The C12orf29 gene product has been provisionally designated C12orf29 pending further characterization.

瀹夸富锛歊bt
绫诲瀷锛歅ab
鍚岀鍨婜IgG
搴旂敤锛歐B
绾寲鏂瑰紡锛氫翰鍜岀函鍖朁br/>鍋惰仈鐗╋細Unconjugated
鎬х姸锛氭恫浣
瀛樺偍婧舵恫锛氬弬闃呰鏄庝功
娴撳害锛欱atch dependent (Please refer to the vial label for the specific concentration.)
绋€閲婃瘮渚婜 Optimal dilutions/concentrations should be determined by the end user
鍌ㄥ瓨锛氱粡甯镐娇鐢ㄥ垯4掳C淇濆瓨銆?20掳C淇濆瓨涓嶈秴杩囦袱骞淬€傞伩鍏嶅弽澶嶅喕铻嶃€侟br/>娉ㄦ剰浜嬮」锛氫粎渚涘疄楠屽浣跨敤銆備笉閫傜敤浜庝汉绫绘垨鍔ㄧ墿鐨勪换浣曚复搴婏紝娌荤枟鎴栬瘖鏂敤閫斻€備笉閫傚悎鍔ㄧ墿鎴栦汉绫婚鐢ㄣ€侟/p>

鐩稿叧浜у搧
Baidu
map